| Novel therapeutic choices in immune aplastic anemia |
|
F1000Research |
Aplastic Anemia |
| Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria |
|
Clinical and Experimental Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Newly revised 2023 MDS response criteria |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes |
|
American Society of Clinical Oncology Educational Book |
Myelodysplastic Syndromes (MDS) |
| New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes |
|
American Society of Clinical Oncology Educational Book |
Myelodysplastic Syndromes (MDS) |
| New Approaches for Anemia in MDS |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Myelodysplastic/myeloproliferative Neoplasm, Unclassifiable (MDS/MPN-U): More Than Just a "Catch-All" Term? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Myelodysplastic Syndromes: Moving Towards Personalized Management |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
